Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining 'optimal' residual disease

Suk Joon Chang, Robert E. Bristow

Research output: Contribution to journalReview articlepeer-review

Abstract

Over the past 40 years, the survival of patients with advanced ovarian cancer has greatly improved due to the introduction of combination chemotherapy with platinum and paclitaxel as standard front-line treatment and the progressive incorporation of increasing degrees of maximal cytoreductive surgery. The designation of "optimal" surgical cytoreduction has evolved from residual disease ≤ 1 cm to no gross residual disease. There is a growing body of evidence that patients with no gross residual disease have better survival than those with optimal but visible residual disease. In order to achieve this, more radical cytoreductive procedures such as radical pelvic resection and extensive upper abdominal procedures are increasingly performed. However, some investigators still suggest that tumor biology is a major determinant in survival and that optimal surgery cannot fully compensate for tumor biology. The aim of this review is to outline the theoretical rationale and historical evolution of primary cytoreductive surgery, to re-evaluate the preferred surgical objective and procedures commonly required to achieve optimal cytoreduction in the platinum/taxane era based on contemporary evidence, and to redefine the concept of "optimal" residual disease within the context of future surgical developments and analysis of treatment outcomes.

Original languageEnglish (US)
Pages (from-to)483-492
Number of pages10
JournalGynecologic oncology
Volume125
Issue number2
DOIs
StatePublished - May 1 2012

Keywords

  • Optimal residual disease
  • Ovarian cancer
  • Primary cytoreductive surgery

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining 'optimal' residual disease'. Together they form a unique fingerprint.

Cite this